FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

734494005: Ruxolitinib phosphate (substance)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2018. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
3507870017 Ruxolitinib phosphate (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
3507871018 Ruxolitinib phosphate en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
839111000172114 phosphate de ruxolitinib fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Ruxolitinib phosphate (substance) Is a Ruxolitinib false Inferred relationship Some
Ruxolitinib phosphate (substance) This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Janus kinase inhibitor (disposition) true Inferred relationship Some
Ruxolitinib phosphate (substance) This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. Ruxolitinib true Inferred relationship Some
Ruxolitinib phosphate (substance) Is a Nitrile true Inferred relationship Some
Ruxolitinib phosphate (substance) Is a Janus kinase inhibitor true Inferred relationship Some
Ruxolitinib phosphate (substance) Is a Pyrazole derivative true Inferred relationship Some
Ruxolitinib phosphate (substance) Is a Enzyme inhibitor false Inferred relationship Some
Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing precisely ruxolitinib (as ruxolitinib phosphate) 5 milligram/1 each conventional release oral tablet (clinical drug) The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Ruxolitinib phosphate (substance) Inferred relationship Some 1
Ruxolitinib (as ruxolitinib phosphate) 10 mg oral tablet The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Ruxolitinib phosphate (substance) Inferred relationship Some 1
Ruxolitinib (as ruxolitinib phosphate) 20 mg oral tablet The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Ruxolitinib phosphate (substance) Inferred relationship Some 1
Product containing precisely ruxolitinib (as ruxolitinib phosphate) 15 milligram/1 each conventional release oral tablet (clinical drug) The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Ruxolitinib phosphate (substance) Inferred relationship Some 1
Ruxolitinib (as ruxolitinib phosphate) 25 mg oral tablet The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Ruxolitinib phosphate (substance) Inferred relationship Some 1

This concept is not in any reference sets

Back to Start